Trastuzumab deruxtecan in previously treated HER2‐positive metastatic or unresectable breast cancer: Real‐life data from the temporary use authorization program in …
T Petit, N Hajjaji, EC Antoine, MA Benderra… - Cancer …, 2024 - Wiley Online Library
Background Early access program (formerly cohort Temporary Authorization for Use) was
granted for trastuzumab deruxtecan (T‐DXd) in France based on DESTINY‐Breast01 trial …
granted for trastuzumab deruxtecan (T‐DXd) in France based on DESTINY‐Breast01 trial …
Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer: Real-life data from the temporary use authorization program in …
T Petit, N Hajjaji, EC Antoine, MA Benderra… - Cancer …, 2024 - europepmc.org
Background Early access program (formerly cohort Temporary Authorization for Use) was
granted for trastuzumab deruxtecan (T-DXd) in France based on DESTINY-Breast01 trial …
granted for trastuzumab deruxtecan (T-DXd) in France based on DESTINY-Breast01 trial …
[HTML][HTML] Trastuzumab deruxtecan in previously treated HER2‐positive metastatic or unresectable breast cancer: Real‐life data from the temporary use authorization …
T Petit, N Hajjaji, EC Antoine, MA Benderra… - Cancer …, 2024 - ncbi.nlm.nih.gov
Background Early access program (formerly cohort Temporary Authorization for Use) was
granted for trastuzumab deruxtecan (T‐DXd) in France based on DESTINY‐Breast01 trial …
granted for trastuzumab deruxtecan (T‐DXd) in France based on DESTINY‐Breast01 trial …
Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer: Real-life data from the temporary use authorization program in …
T Petit, N Hajjaji, EC Antoine… - Cancer …, 2024 - pubmed.ncbi.nlm.nih.gov
Background Early access program (formerly cohort Temporary Authorization for Use) was
granted for trastuzumab deruxtecan (T-DXd) in France based on DESTINY-Breast01 trial …
granted for trastuzumab deruxtecan (T-DXd) in France based on DESTINY-Breast01 trial …
Trastuzumab deruxtecan in previously treated HER2‐positive metastatic or unresectable breast cancer: Real‐life data from the temporary use authorization program in …
T Petit, N Hajjaji, EC Antoine, MA Benderra… - Cancer …, 2024 - search.ebscohost.com
Background: Early access program (formerly cohort Temporary Authorization for Use) was
granted for trastuzumab deruxtecan (T‐DXd) in France based on DESTINY‐Breast01 trial …
granted for trastuzumab deruxtecan (T‐DXd) in France based on DESTINY‐Breast01 trial …